Comparing the current results to its competitors, Longeveron Inc reported Revenue decrease in the 2 quarter 2026 year on year by -9.18 %, slower than the combined decrease of the LGVN's competitors by -22.21 %, recorded in the same quarter.
Longeveron Inc 's Comment on Competition and Industry Peers
The company utilizes a scalable manufacturing process, proprietary technologies, and an experienced team to establish competitive barriers. It occasionally offers contract manufacturing and development services to third parties, though business development in this area is limited. On February 21, 2024, the company entered into a five-year Supply Agreement with a third-party biotechnology company developing mu. The company relies on patents, trademarks, trade secrets, know-how, and ongoing innovation to maintain its competitive position but recognizes risks related to patent challenges, trade secret breaches, and independent competitor development. Additionally, orphan drug designations and exclusivity provide some protection, though competitors may obtain approvals for different products or indications. The company faces competition from lower-priced pharmaceutical products in foreign countries with price controls and imported products. Reimbursement policies and healthcare reforms may also affect profitability and market competition.
despite revenue deterioration, Longeveron Inc increased its market share in this segment. company increased its market share in this segment to approximately 0.17 %.
June 3, 2024
Longeveron Announces Contract Development and Manufacturing Business and First ContractLongeveron, a leading biotechnology company specializing in regenerative medicine, has recently announced the launch of its new contract development and manufacturing business for stem cell therapies. This marks a significant milestone for the company as it aims to expand its capabilities and offer its expertise to other organizations in the field.The contract development and manufacturing business will operate from Longeveron s brand-new, state-of-the-art facility spanning 15,000 square feet, which boasts eight cleanrooms built following current Good Manufacturing Practice (cGMP) guidelines. This cutting-edge facility is ...
2seventy Bio Inc operates on a business model centered around the development and commercialization of innovative genetic therapies. They strive to harness the power of biotechnology to address complex diseases and improve patient outcomes. By advancing their proprietary gene delivery technologies and collaborating with industry partners, they aim to create scalable treatments that revolutionize the field of genetic medicine.
Hookipa Pharma Inc. is a biotechnology company that focuses on developing immunotherapeutics targeting infectious diseases and various forms of cancer. Their business model revolves around leveraging their proprietary technology platform, known as VaxWave, to design and manufacture a new class of immunotherapies. By collaborating with strategic partners and conducting clinical trials, Hookipa aims to bring these innovative treatments to market to improve patient outcomes and address unmet medical needs.
Sources:
Longeveron Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Longeveron Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
